Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer
Abstract
Poly (ADP ribose)-polymerase (PARP) inhibitors are approved for use in breast, ovarian, prostate, and pancreatic cancers, which are the solid tumor types that most frequently have alterations in key homologous recombination (HR) genes, such as BRCA1/2. However, the frequency of HR deficiency (HRD) in other solid tumor types, including bladder cancer, is less well characterized.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 04, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-5037
Entities
People
- Aurel Prosz
- Dag Rune Stormoen
- Helle Pappot
- István Csabai
- Judit Börcsök
- Kent W. Mouw
- Miklos Diossy
- Orsolya Rusz
- Sándor Spisák
- Søren Brunak
- Viktoria Tisza
- Zoltán Szállási
- Zsófia Sztupinszki
Organizations
- Boston Children's Hospital
- Dana–Farber Cancer Institute
- Danish Cancer Society
- Danish Council for Independent Research | Medical Sciences
- Eötvös Loránd University
- National Cancer Institute
- Novo Nordisk Fonden
- Semmelweis University
- The Breast Cancer Research Foundation
- University of Copenhagen
- Velux Stiftung